Published online before print November 17, 2005, doi: 10.1161/01.RES.0000196578.15385.bb
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 25, 2005
Revised on October 12, 2005
Accepted on November 3, 2005
Phospholipase C 
Modulates 
-Adrenergic Receptor Dependent Cardiac Contraction and Inhibits Cardiac Hypertrophy
Huan Wang ;
From the Departments of Pharmacology and Physiology (H.W., E.A.O., R.T.D., B.C.B., A.V.S.) and Biochemistry and Biophysics (H.W., A.V.S.) and the Cardiovascular Research Institute (N.M., T.A.B., B.C.B.), University of Rochester School of Medicine, Rochester, NY; and Departments of Pharmacology (K.L.V., G.G.K.) and Medicine (G.G.K.), State University of New York Upstate Medical University, Syracuse.
* To whom correspondence should be addressed. E-mail: Alan_Smrcka{at}URMC.rochester.edu.
Phospholipase C (PLC) 
is a recently identified enzyme regulated by a wide range of molecules including Ras family small GTPases, Rho A, G
12/13, and G
with primary sites of expression in the heart and lung. In a screen for human signal transduction genes altered during heart failure, we found that PLC mRNA is upregulated. Two murine models of cardiac hypertrophy confirmed upregulation of PLC protein expression or PLC RNA. To identify a role for PLC in cardiac function and pathology, a PLC-deficient mouse strain was created. Echocardiography indicated PLC-/- mice had decreased cardiac function, and direct measurements of left ventricular contraction demonstrated that PLC-/- mice had a decreased contractile response to acute isoproterenol administration. Cardiac myocytes isolated from PLC-/- mice had decreased -adrenergic receptor (AR)-dependent increases in Ca2+ transient amplitudes, likely accounting for the contractile deficiency in vivo. This defect appears to be independent from the ability of the AR system to produce cAMP and regulation of sarcoplasmic reticulum Ca2+ pool size. To address the significance of these functional deficits to cardiac pathology, PLC-/- mice were subjected to a chronic isoproterenol model of hypertrophic stress. PLC-/- mice were more susceptible than wild-type littermates to development of hypertrophy than wild-type littermates. Together, these data suggest a novel PLC-dependent component of AR signaling in cardiac myocytes responsible for maintenance of maximal contractile reserve and loss of PLC signaling sensitizes the heart to development of hypertrophy in response to chronic cardiac stress.
Key words: phospholipase C •
-adrenergic receptor •
heart failure •
contractility
This article has been cited by other articles:
 |
|
 |
|
  T. M. Filtz, D. R. Grubb, T. J. McLeod-Dryden, J. Luo, and E. A. Woodcock Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase C{beta}1b FASEB J, October 1, 2009; 23(10): 3564 - 3570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Harden, S. N. Hicks, and J. Sondek Phospholipase C isozymes as effectors of Ras superfamily GTPases J. Lipid Res., April 1, 2009; 50(Supplement): S243 - S248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Oestreich, S. Malik, S. A. Goonasekera, B. C. Blaxall, G. G. Kelley, R. T. Dirksen, and A. V. Smrcka Epac and Phospholipase C{epsilon} Regulate Ca2+ Release in the Heart by Activation of Protein Kinase C{epsilon} and Calcium-Calmodulin Kinase II J. Biol. Chem., January 16, 2009; 284(3): 1514 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Seifert, Y. Zhou, S. N. Hicks, J. Sondek, and T. K. Harden Dual Activation of Phospholipase C-{epsilon} by Rho and Ras GTPases J. Biol. Chem., October 31, 2008; 283(44): 29690 - 29698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lowik, E. Levtchenko, D. Westra, P. Groenen, E. Steenbergen, J. Weening, M. Lilien, L. Monnens, and L. v. d. Heuvel Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3146 - 3151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yun, A. Moller, S.-K. Chae, W.-P. Hong, Y. J. Bae, D. D. L. Bowtell, S. H. Ryu, and P.-G. Suh Siah Proteins Induce the Epidermal Growth Factor-dependent Degradation of Phospholipase C{epsilon} J. Biol. Chem., January 11, 2008; 283(2): 1034 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ikuta, H. Edamatsu, M. Li, L. Hu, and T. Kataoka Crucial Role of Phospholipase C{varepsilon} in Skin Inflammation Induced by Tumor-Promoting Phorbol Ester Cancer Res., January 1, 2008; 68(1): 64 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 >A. V. Smrcka, E. A. Oestreich, B. C. Blaxall, and R. T. Dirksen EPAC regulation of cardiac EC coupling J. Physiol., November 1, 2007; 584(3): 1029 - 1031. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Citro, S. Malik, E. A. Oestreich, J. Radeff-Huang, G. G. Kelley, A. V. Smrcka, and J. H. Brown Phospholipase C{varepsilon} is a nexus for Rho and Rap-mediated G protein-coupled receptor-induced astrocyte proliferation PNAS, September 25, 2007; 104(39): 15543 - 15548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Oestreich, H. Wang, S. Malik, K. A. Kaproth-Joslin, B. C. Blaxall, G. G. Kelley, R. T. Dirksen, and A. V. Smrcka Epac-mediated Activation of Phospholipase C{epsilon} Plays a Critical Role in beta-Adrenergic Receptor-dependent Enhancement of Ca2+ Mobilization in Cardiac Myocytes J. Biol. Chem., February 23, 2007; 282(8): 5488 - 5495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kang, O. G. Chepurny, B. Malester, M. J. Rindler, H. Rehmann, J. L. Bos, F. Schwede, W. A. Coetzee, and G. G. Holz cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic {beta} cells and rat INS-1 cells J. Physiol., June 15, 2006; 573(3): 595 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hains, M. R. Wing, S. Maddileti, D. P. Siderovski, and T. K. Harden G{alpha}12/13- and Rho-Dependent Activation of Phospholipase C-{epsilon} by Lysophosphatidic Acid and Thrombin Receptors Mol. Pharmacol., June 1, 2006; 69(6): 2068 - 2075. [Abstract] [Full Text] [PDF]
|
|